Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,646 Mln
Revenue (TTM)
$376 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
14
Industry P/E
--
EV/EBITDA
1426.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$1.5
EPS
$-0.1
Face value
--
Shares outstanding
124,033,382
CFO
$-853.13 Mln
EBITDA
$-943.92 Mln
Net Profit
$-991.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arcutis Biotherapeutics Inc (ARQT)
| -17.0 | -10.6 | -17.0 | 54.1 | 29.9 | -3.6 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Arcutis Biotherapeutics Inc (ARQT)
| 108.5 | 326.2 | -78.2 | -28.6 | -26.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arcutis Biotherapeutics Inc (ARQT)
|
24.1 | 2,645.6 | 376.1 | -16.1 | -0.8 | -9.3 | -- | 14.0 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and... atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361 Read more
President, CEO & Director
Mr. Todd Franklin Watanabe M.A.
President, CEO & Director
Mr. Todd Franklin Watanabe M.A.
Headquarters
Westlake Village, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Arcutis Biotherapeutics Inc (ARQT) is $24.10 (NASDAQ) as of 01-Apr-2026 16:01 EDT. Arcutis Biotherapeutics Inc (ARQT) has given a return of 29.88% in the last 3 years.
Since, TTM earnings of Arcutis Biotherapeutics Inc (ARQT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-228.49
|
19.46
|
|
2024
|
-12.04
|
10.70
|
|
2023
|
-0.85
|
2.51
|
|
2022
|
-2.61
|
3.88
|
|
2021
|
-4.94
|
3.41
|
The 52-week high and low of Arcutis Biotherapeutics Inc (ARQT) are Rs 31.77 and Rs 11.86 as of 02-Apr-2026.
Arcutis Biotherapeutics Inc (ARQT) has a market capitalisation of $ 2,646 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Arcutis Biotherapeutics Inc (ARQT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.54
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.